Cytogen싸이토젠
217330 · KOSDAQ · ₩217330 · 싸이토젠
- Market cap
- ₩57B
- Enterprise value
- ₩47B
- P/E
- —
- P/B
- 1.7×
- Dividend yield
- 0.0%
- ROE
- −31.6%
- Net margin
- −38.5%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−78.1% from the high
₩2,435Today: ₩2,435 – ₩2,630₩11,200
Returns
- 1W−8.1%
- 1M−19.0%
- 3M−19.0%
- 6M−57.1%
- YTD−72.7%
- 1Y−18.5%
- Volume today
- 48,932
- 0.8× the 20-day average
- Traded today
- ₩121M
- Listed shares
- 23,129,547
- EPS (12 months)
- −₩456
- Earnings yield −18.6%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 37 of 100 (50 is a normal day for this stock).
- MomentumWeak-18.5% over the last month; the price is below its 20-day average.
- News impactLow1 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Cytogen stock overview
Cytogen (싸이토젠, KRX: 217330) is listed on KOSDAQ, in the Biotech & Pharma sector. Cytogen is a Korean global total healthcare company built around liquid biopsy using its proprietary Live CTC (circulating tumor cell) isolation technology. Its shares closed at ₩2,450 on Oct 27, 2026, down 2.00% on the day, giving it a market value of ₩57B.
Key facts
- Market cap
- ₩57B
- Sector
- Biotech & Pharma
- Latest price change
- −2.00%
- As of
- Oct 27, 2026
- Main business
- Cytogen is a Korean global total healthcare company built around liquid biopsy using its proprietary Live CTC (circulating tumor cell) isolation technology.
Quick answers about Cytogen
- What does Cytogen do?
- Cytogen is a Korean global total healthcare company built around liquid biopsy using its proprietary Live CTC (circulating tumor cell) isolation technology. Its core Smart Biopsy platform provides CTC-based biomarker discovery, validation, and companion diagnostic assay development services to pharmaceutical companies for anticancer drug development, and also supplies platform equipment and kits to research institutions. The company also distributes medical devices and pharmaceuticals through pharmacies, hospitals and wholesalers, sells health supplements online, and operates in the United States and Japan.
- What is the market cap of Cytogen?
- The market capitalisation of Cytogen was ₩57B at the close on Oct 27, 2026.
- Who are the largest shareholders of Cytogen?
- According to the latest official filings, the largest reported holders are Candy X Holdings (41.30%, as of Oct 12, 2026); Jeon Byeong-hee (8.84%, as of Oct 12, 2026); Kim Jin-uk (3.62%, as of Jan 7, 2025).
- When is the next earnings report from Cytogen?
- Korean companies rarely announce results dates in advance. Based on when Cytogen filed the same report in past years, its next 3q results is expected between Nov 13, 2026 and Nov 29, 2026.
Company profile
Cytogen is a Korean global total healthcare company built around liquid biopsy using its proprietary Live CTC (circulating tumor cell) isolation technology. Its core Smart Biopsy platform provides CTC-based biomarker discovery, validation, and companion diagnostic assay development services to pharmaceutical companies for anticancer drug development, and also supplies platform equipment and kits to research institutions. The company also distributes medical devices and pharmaceuticals through pharmacies, hospitals and wholesalers, sells health supplements online, and operates in the United States and Japan.
Written by AI from the company's latest annual report.
- Korean name
- 싸이토젠
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 안지훈
- Founded
- Mar 2010
- Listed
- Nov 2018
- Listed shares
- 23,129,547
- Fiscal year ends
- Month 12
- Website
- cytogenlab.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- Amended: Major sales or supply contractOct 20, 2026
- 5%+ holding reportOct 12, 2026
- Insider shareholding reportOct 12, 2026
- 5%+ holding reportOct 12, 2026
- Merger Completion Report (Merger)Oct 1, 2026
Titles in Korean until English translations are added.
Also known as: Cytogen / 싸이토젠 / 217330 / KRX:217330
Source: KRX statistical information